Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medexus PharmaceuticalsFRA:P731 58 3-1 Month Momentum % is 28.57% as of Sep. 11, 2026. GuruFocus rates FRA:P731 with a GF Score™ of 58/100 and a GF Value™ of €1.23 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Medexus Pharmaceuticals ranks better than 87.49% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-11), Medexus Pharmaceuticals's 3-1 Month Momentum % is 28.57%.
The industry rank for Medexus Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
FRA:P731's 3-1 Month Momentum % is ranked better than 87.49% of 1023
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs FRA:P731: 28.57
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Medexus Pharmaceuticals 3-1 Month Momentum % Related Terms
FRA:P731 vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (FRA:P731) has a 3-1 Month Momentum % of 28.57% as of Sep. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medexus Pharmaceuticals and its competitors. According to the industry distribution chart, Medexus Pharmaceuticals ranks #128 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 12.5%.
Is Medexus Pharmaceuticals' 3-1 Month Momentum % too high?
Medexus Pharmaceuticals' current 3-1 Month Momentum % is 28.57%. The Drug Manufacturers industry median 3-1 Month Momentum % is 3.13. Medexus Pharmaceuticals' value of 28.57% is 812.8% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #128 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #128 out of 1023 companies for 3-1 Month Momentum %. This places Medexus Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 3.13. Medexus Pharmaceuticals' value of 28.57% is 812.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 3.13, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current 3-1 Month Momentum % of 28.57% is 812.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current 3-1 Month Momentum % is 28.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (FRA:P731) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.23, compared to a current price of €3.10 — trading 152% above its estimated fair value. The current 3-1 Month Momentum % is 28.57% and 812.8% above the Drug Manufacturers industry median of 3.13. Medexus Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Medexus Pharmaceuticals (FRA:P731), the current 3-1 Month Momentum % is 28.57% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (FRA:P731) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of €3.10 is trading 152% above its estimated GF Value™ of €1.23.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:P731:
3-1 Month Momentum %: 28.57%
GF Value™: €1.23 vs. price of €3.10 (152% above fair value)
Industry Position: 812.8% above the Drug Manufacturers median (#128 of 1023)
No single metric tells the full story. See the FRA:P731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
58GF Score
Get the complete analysis for FRA:P731
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P731 has been successfully added to your 
